Protagonist Therapeutics, Inc: depreciation expense
Depreciation expense for Protagonist Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Protagonist Therapeutics, Inc financial histories
What this measure means
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
Exact concept: us-gaap:Depreciation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 1,225,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019696 |
| 2024-01-01 | 2024-12-31 | 894,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019696 |
| 2023-01-01 | 2023-12-31 | 977,000 | USD | 2026-02-25 | 10-K · 0001104659-26-019696 |
| 2022-01-01 | 2022-12-31 | 1,032,000 | USD | 2025-02-21 | 10-K · 0001558370-25-001317 |
| 2021-01-01 | 2021-12-31 | 813,000 | USD | 2024-02-27 | 10-K · 0001558370-24-001850 |
| 2020-01-01 | 2020-12-31 | 789,000 | USD | 2023-03-15 | 10-K · 0001558370-23-003906 |
| 2019-01-01 | 2019-12-31 | 703,000 | USD | 2022-02-28 | 10-K · 0001558370-22-002385 |
| 2018-01-01 | 2018-12-31 | 527,000 | USD | 2021-03-10 | 10-K · 0001558370-21-002715 |
| 2017-01-01 | 2017-12-31 | 406,000 | USD | 2020-03-10 | 10-K · 0001558370-20-002334 |
| 2016-01-01 | 2016-12-31 | 317,000 | USD | 2019-03-12 | 10-K · 0001558370-19-001853 |
| 2015-01-01 | 2015-12-31 | 247,000 | USD | 2018-03-07 | 10-K · 0001558370-18-001637 |
| 2014-01-01 | 2014-12-31 | 258,000 | USD | 2017-03-07 | 10-K · 0001193125-17-073383 |
Related financial histories
- Protagonist Therapeutics, Inc: total assets
- Protagonist Therapeutics, Inc: total liabilities
- Protagonist Therapeutics, Inc: stockholders equity
- Protagonist Therapeutics, Inc: cash and cash equivalents
- Protagonist Therapeutics, Inc: net income or loss
- Protagonist Therapeutics, Inc: operating cash flow
- Protagonist Therapeutics, Inc: capital expenditure payments
- Protagonist Therapeutics, Inc: financing cash flow
- Protagonist Therapeutics, Inc: investing cash flow
- Protagonist Therapeutics, Inc: retained earnings or deficit
- Protagonist Therapeutics, Inc: basic weighted-average shares
- Protagonist Therapeutics, Inc: diluted weighted-average shares
- Protagonist Therapeutics, Inc: basic earnings per share
- Protagonist Therapeutics, Inc: diluted earnings per share
- Protagonist Therapeutics, Inc: income tax expense or benefit
- Protagonist Therapeutics, Inc: net property, plant and equipment
- Protagonist Therapeutics, Inc: share-based compensation expense
- Protagonist Therapeutics, Inc: operating income or loss
- Protagonist Therapeutics, Inc: current assets
- Protagonist Therapeutics, Inc: current liabilities
- Protagonist Therapeutics, Inc: current accounts payable
- Protagonist Therapeutics, Inc: operating expenses
- Protagonist Therapeutics, Inc: research and development expense
- Protagonist Therapeutics, Inc: common shares outstanding
- Protagonist Therapeutics, Inc: cash including restricted cash
- Protagonist Therapeutics, Inc: accumulated other comprehensive income or loss
- Protagonist Therapeutics, Inc: operating lease right-of-use asset
- Protagonist Therapeutics, Inc: operating lease liability
- Protagonist Therapeutics, Inc: gross property, plant and equipment
- Protagonist Therapeutics, Inc: accumulated depreciation on property, plant and equipment
- Protagonist Therapeutics, Inc: accrued current liabilities
- Protagonist Therapeutics, Inc: prepaid expenses and other current assets
- Protagonist Therapeutics, Inc: current contract liabilities
- Protagonist Therapeutics, Inc: pre-tax income or loss from continuing operations
- Protagonist Therapeutics, Inc: profit or loss including noncontrolling interests
- Protagonist Therapeutics, Inc: comprehensive income or loss
- Protagonist Therapeutics, Inc: net income available to common stockholders
- Protagonist Therapeutics, Inc: general and administrative expense
- Protagonist Therapeutics, Inc: depreciation, depletion and amortization
- Protagonist Therapeutics, Inc: other nonoperating income or expense
- Protagonist Therapeutics, Inc: current income tax expense or benefit
- Protagonist Therapeutics, Inc: deferred income tax expense or benefit
- Protagonist Therapeutics, Inc: proceeds from issuing common stock
- Protagonist Therapeutics, Inc: operating lease payments
- Protagonist Therapeutics, Inc: change in accounts payable
Inspect the source
- Entity
- Protagonist Therapeutics, Inc / CIK 0001377121
- Captured
- 2026-09-20T07:57:41.966Z
- SEC response SHA-256
2b94be6cb332c7a26793b651bf94eb30da9e478dc7b731b5866c637778540431
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001377121.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))